Their analysis showed that the mTOR inhibitor MLN0128 could suppress tumor growth and glycolysis in genetically engineered mouse models (GEMMs) of lung cancer with KRAS and LKB1 co-mutations, as shown by reduced 18F-FDG consumption [342]. The gene discussed is KRAS; the disease is neoplasm.